Ovarian Cancer and Cancer

Phenoxodiol, a Medication for Cancer

Clinical studies have predominantly focused on a couple of standard benzopyrans, namely flavopiridol and phenoxodiol (by Novogen, via MEI Pharma, the company's subsidiary at the time). Although a benzopyran, the former's method of action apparently differs from phenoxodiol's action neither of the two aforementioned benzopyrans has gained FDA (Food and Drug Administration) or EMA (European Medicines Agency) approval. The height of research on phenoxodiol was one 'Phase III' research on resistant cancer cells in the ovaries. Although slow recruitment led the trial at this phase to formally close down, results clearly displayed that oral consumption of phenoxodiol would most probably not have benefited patients, if the trial phase had been completed. Phenoxodiol results (in combination with others) led to the following hypothesis by Novogen: the problem with phenoxodiol pertained to bioavailability (in other words, the ingested drug wasn't reaching the site of cancer in adequate quantities); thus, there was a lack of adequate activity at the site of the cancer (Marc Sinatra, 2015).

The project which resulted in Cantrixil's development was, apparently, initially focused on seeking phenoxodiol's successor to treat ovarian cancer. While the end product of the experiment is nevertheless associated with ovarian cancer, it is being aimed at pleural and peritoneal cancers. Further, organizations and the involved executive team have a superior grasp of available technologies (Marc Sinatra, 2015).

Presenting Phenoxodiol with improved Solution

Phenoxodiol represents an isoflavone equivalent with antitumor function against several kinds of cancers. The researchers of a recent study explored phenoxodiol's impacts on cancer cells in the human gallbladder, in an attempt to ascertain if phenoxodiol was capable of enhancing gemcitabine antitumor activity in case of gallbladder cancer. A combination of gemcitabine-phenoxodiol proved to be a more potent treatment, when it came to cell proliferation inhibition, as compared to both chemotherapeutic agents alone. Moreover, antitumor impacts of a gemcitabine-phenoxodiol combination on cancer cells in the gallbladder was studied via a mouse xenograft model for gallbladder cancer; results indicated that phenoxodiol led to enhanced in-vivo gemcitabine antitumor activity. Taken together, the research work indicated that gemcitabine-phenoxodiol combination treatment can provide optimal therapeutic advantages for gallbladder-cancer patients (Yu Li, Xiaoqiang Huang, Zhiqiang Huang, & Jian Feng, 2014). Phenoxodiol represents a new-gen anti-cancer medication coming under the 'signal transduction inhibitor' category of drugs, which induce programmed cancer-cell death (apoptosis), and have no or minimal impact on the normal cells in the patient's body (Marshall Edwards Inc., 2003).

FDA Standpoint

The Food and Drug Administration's oncology department issued a research report in the year 2015 revealing that the general response rate or tumor shrinkage, which is the alternate endpoint for quicker approval, is related to progression-less survival (that is, the disease is controlled for longer), most markedly in case of molecularly targeted treatments. However, the endpoint did not exhibit a strong correlation to overall survival -- possibly because of novel targeted treatments' highly remarkable benefits, which cause a majority of patients to shift to the trial's treatment arm prior to completion. Hence, it becomes impossible to gauge survival on the whole against care standards. Arguably, when one encounters a substantial response rate, even randomizing trial within a target patient group may be considered unethical (Paul Howard, 2015).

Phenoxodiol and other cancer treatments continue to face increasing challenges.

Steps to strongly facilitate FDA approval of novel cancer treatments include (U.S. Department of Health and Human Services, 1998).

1. FDA consideration of recommendations from all sources of promising novel cancer treatment indicators for existing marketed drugs that must be looked into for potential inclusion in the labeling process.